Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund
This article was originally published in Start Up
The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.
You may also be interested in...
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.
Rare disease start-up scores Series A financing and technology patents to develop a treatment for a deadly genetic disorder.